test

Mario Sznol MD

Professor of Medicine (Medical Oncology); Clinical Research Program Leader, Melanoma Program, Yale Cancer Center; Co-Director, Yale SPORE in Skin Cancer

Clinical Interests

melanoma; immunologic therapy; renal cell (kidney) carcinoma; Phase I trials


Board Certifications

1985
Internal Medicine, Board Certified
1987
Medical Oncology, Board Certified

Patient Care Locations

mario_sznolfaculty-clinicsfalsetruetrue6truefalsefalse

Clinical Trials

ConditionsStudy Title
Lung and Melanoma, skinA Phase 2 Study of MK-3475 in patients with metastatic melanoma and non-small cell lung cancer with untreated brain metastases
KidneyA PHASE II, RANDOMIZED STUDY OF MPDL3280A ADMINISTERED AS MONOTHERAPY OR IN COMBINATION WITH BEVACIZUMAB VERSUS SUNITINIB IN PATIENTS WITH UNTREATED ADVANCED RENAL CELL CARCINOMA
Expanded Access of MK-3475 in Metastatic Melanoma Patients with Limited to No Treatment Options
Melanoma, skinPhase I Dose Escalation, Safety, Pharmacokinetic and Pharmacodynamic Study of BVD-523 in Patients with Advanced Malignancies
Active Surveillance of the Small Renal Mass: An Integrated Biomarker Trial

More Clinical Trials...

Edit Profile